Valuable Pointers For Maximising Sales Force Effectiveness

During the serious recession of 2008 and 2009, the healthcare industry was one of the few actual growth areas, just as the USA was in the news due to the president’s intended healthcare reform and the consequent, lengthy delays in Congress. Indeed, the healthcare business was a pivotal part of Obama’s campaign and he wasted no time in prompting both houses of Congress to consider change. Could it be that we are poised for a momentous change in this industry, one which will reach every person in the country, ranging from individuals through insurance companies, hospitals to pharmaceutical companies? Now more than ever, the role of healthcare and pharmaceutical consulting organisations will be tested and they will need to bring all their skills to the table to process changes that are sure to come.

Healthcare will be a growing industry for the foreseeable future, especially as the generation known as “baby boomers” comes of a certain age, representing a strain on the overall health care system. This will call for innovation and the provision of additional services and products by the pharmaceutical company. The marketplace is sure to get more and more competitive.

A spotlight will always be trained on costs and the role of the insurance company as intermediary between both ends of the spectrum. Healthcare professionals are sure to receive pressure, as they weigh up the advice that they should give their patients in the light of new rules and rafts of legislation. All in all, a great period of uncertainty can be expected in what is already a pressure filled industry.

In the future, pharmaceutical consultants, already in high demand, will be even more valuable as the role of pharma consulting extends to decipher these new rules and implications. A company’s workforce will benefit from the training provided by these consultants, as they deliver results and draw on years of experience, training and expertise. The parent company’s executives have much to do dealing with the daily concerns and requirements associated with regulatory pressures and production issues. Their valuable time should be devoted to the administration of staff, training and maintenance. The pharmaceutical consulting firm is ready and able to take on this element of the organisation and to ensure that sales executives implement correctly and bring as valuable a return as possible to the company’s bottom line.

The healthcare business is one of our most dynamic industries and pharmaceutical and healthcare consulting is a critical internal component. The pharmaceutical company faces significant pressures from a wide variety of interested parties, not all of whom can be considered to be “friendly.” While the company’s executives struggle with these issues, figuring out how to interpret positions and trying to devise how to approach and deal with each party from a strong position, the pharmaceutical consulting firm can provide valuable backing. Make no mistake, there are challenging and risky times ahead, yet these times could also be potentially lucrative and the consultant can be an additional pair of ears and eyes, together with a valued resource. The company is advised to consider a long-term engagement with the pharmaceutical and healthcare consulting firm accordingly.

Alan Gillies is the Managing Director of L2L Consulting, specialising in enabling pharmaceutical companies to achieve new heights of productivity and performance, throughout all levels of management and revenue generating activities.